Item 2.02 Results of Operations and Financial Condition.
As previously announced, Dr. Vimal Mehta, Founder and Chief Executive Officer of
BioXcel Therapeutics, Inc. (the “Company”), will be providing a presentation at
the 40th Annual J.P. Morgan Healthcare Conference (the “Conference”) on
Thursday, January 13, 2022 at 9:45 a.m., Eastern Time. In connection with the
presentation, the Company expects to report that the Company’s estimated cash
position as of December 31, 2021 totaled approximately $233 million. This
estimate is unaudited and preliminary and does not present all information
necessary for an understanding of the Company’s financial condition as of
December 31, 2021 and its results of operations for the three months and year
ended December 31, 2021. The completion of the Company’s year-end accounting
procedures, including execution of the Company’s internal control over financial
reporting, and audit of the Company’s financial statements for the year ended
December 31, 2021 by the Company’s independent registered public accounting firm
is ongoing and could result in changes to the information set forth above.
Item 7.01 Regulation FD Disclosure.
The live webcast and a copy of the accompanying presentation materials that will
be used at the Conference will be available through the Investors page of the
Company’s website at http://www.bioxceltherapeutics.com. A replay of the webcast
will be available on the Company’s website for 30 days following the event.
The information in this Current Report on Form 8-K shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall it be deemed to be incorporated by reference into any filing of the
Company under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such filing.
Statements in this Form 8-K regarding management’s future expectations, beliefs,
intentions, goals, strategies, plans or prospects are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited, to statements regarding the Company’s expected
presentation and the estimated cash balance as of December 31, 2021 the Company
expects to report. Forward-looking statements may be identified by words such as
“anticipates,” “believe,” “continue,” “expect,” “intend,” “may,” “plan to,”
“potential,” “projects,” “will,” and other similar words or expressions, or the
negative of these words or similar words or expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other important
factors, including, without limitation, the risks referred to under the section
“Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2021, as such factors may be updated from time to
time in the Company’s other filings with the Securities and Exchange Commission
(“SEC”), which filings are accessible on the SEC’s website at http://www.sec.gov and
the Investors page of the Company’s website at
http://www.bioxceltherapeutics.com. All forward-looking statements speak only as
of the date of this Form 8-K and, except as required by applicable law, the
Company has no obligation to update or revise any forward-looking statements
contained herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
© Edgar Online, source Glimpses